Intrathecal pemetrexed for leptomeningeal metastases in a patient with ALK-rearranged lung adenocarcinoma: a case report.

Cancer Chemother Pharmacol

Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford Cancer Institute, Stanford, USA.

Published: December 2024

Progressive leptomeningeal metastases (LM) are associated with intractable neurological symptoms and a poor prognosis, and effective treatment options are limited. Intrathecal (IT) pemetrexed has been shown to confer clinical benefit in lung adenocarcinoma, yet our understanding of the efficacy and safety of the treatment is limited. We report a patient with a long-standing history of leptomeningeal disease due to ALK-positive adenocarcinoma of the lung, previously controlled by increased doses of lorlatinib (125 mg/day). Rapid LM progression prompted the start of IT pemetrexed, after which the patient experienced immediate clinical improvement. The case provides additional support that IT pemetrexed can offer symptomatic relief and may be considered as a treatment option in advanced LM. Furthermore, the case illustrates that an increased dose of lorlatinib may efficiently control LM in patients with ALK-rearranged NSCLC, following progression on standard lorlatinib dosage.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-024-04735-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11652564PMC

Publication Analysis

Top Keywords

intrathecal pemetrexed
8
leptomeningeal metastases
8
lung adenocarcinoma
8
pemetrexed leptomeningeal
4
metastases patient
4
patient alk-rearranged
4
alk-rearranged lung
4
adenocarcinoma case
4
case report
4
report progressive
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!